Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management-Reference-Cited by-同舟云学术

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

Published:2022-06 Issue:4 Volume:23 Page:320-332
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Veillon Remi,Sakai Hiroshi^ORCID,Le Xiuning,Felip Enriqueta,Cortot Alexis B.,Smit Egbert F.,Park Keunchil^ORCID,Griesinger Frank,Britschgi Christian,Wu Yi-Long,Melosky Barbara,Baijal Shobhit,Jr Gilberto de Castro,Sedova Michaela,Berghoff Karin,Otto Gordon,Paik Paul K.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference51 articles.

1. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression;Awad;J Clin Oncol,2016

2. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping;Paik;Cancer Discov,2015

3. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

4. Comprehensive molecular profiling of lung adenocarcinoma;Nature,2014

5. New verse for a familiar song: small molecule inhibitors for MET exon 14 skipping non-small cell lung cancer;Le;Oncologist,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explainable machine learning prediction of edema adverse events in patients treated with tepotinib;Clinical and Translational Science;2024-09

2. Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring MET Ex14 skipping: have we met the desired drug?;Translational Lung Cancer Research;2024-06

3. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION;British Journal of Cancer;2024-04-04

4. Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study;Cancer Science;2024-02-25

5. Lung Cancer;Side Effects of Cancer Therapy;2024